Pharmaceutical

Image

Global Transthyretin Amyloid Cardiomyopathy Treatment Market - Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Upcoming Report
  • Jan 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Transthyretin Amyloid Cardiomyopathy Treatment Market, By Drug (Inostersen, Nonsteroidal Anti-Inflammatory Drugs (NSAID), Partisiran, Tafamidis, Others), Indication (Wild Type ATTR Amyloidosis, Hereditary ATTR Amyloidosis), End- Users (Hospitals, Homecare, Specialty Clinics, Ambulatory Surgical Centers, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Country (U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa) Industry Trends and Forecast to 2029.

Transthyretin Amyloid Cardiomyopathy Treatment Market

Market Analysis and Insights Global Transthyretin Amyloid Cardiomyopathy Treatment Market

The transthyretin amyloid cardiomyopathy treatment market is expected to witness market growth at a rate of 25.1% in the forecast period of 2022 to 2029, and is estimated to reach the value of USD 29283.20 million by 2029. Data Bridge Market Research report on transthyretin amyloid cardiomyopathy treatment market provides analysis and insights regarding the various factors expected to be prevalent throughout the forecast period while providing their impacts on the market’s growth. The rise in healthcare sector globally is escalating the growth of transthyretin amyloid cardiomyopathy treatment market.

Transthyretin amyloid cardiomyopathy (ATTR-CM) refers to a form of transthyretin amyloidosis (ATTR) that tends to affect the heart. This condition leads to restrictive cardiomyopathy and progressive heart failure. The disorder is known to be a rare, underdiagnosed, and life-threatening disease and causes damage to the heart’s muscles.

The surge in the number of people suffering from transthyretin amyloid cardiomyopathy across the globe acts as one of the major factors driving the growth of transthyretin amyloid cardiomyopathy treatment market. The increase in demand for specific drugs for treating symptoms of the rare disorder and improvement in diagnostic procedures for better diagnosis accelerate the market growth. The increase in in number of clinical trials for enhancement of drugs and therapies, and high focus on research and development of transthyretin amyloid cardiomyopathy (ATTR-CM) treatment further influence the market. Additionally, rise in healthcare expenditure, research and development activities, growth in awareness and improvement of healthcare services positively affect the transthyretin amyloid cardiomyopathy treatment market. Furthermore, development of a novel drug products extend profitable opportunities to the market players in the forecast period of 2022 to 2029.

On the other hand, high cost associated with the treatment and lack of diagnosis are expected to obstruct the market growth. Lack of skilled professionals is projected to challenge the transthyretin amyloid cardiomyopathy treatment market in the forecast period of 2022-2029.

This transthyretin amyloid cardiomyopathy treatment market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info transthyretin amyloid cardiomyopathy treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth. 

Global Transthyretin Amyloid Cardiomyopathy Treatment Market Scope and Market Size

The transthyretin amyloid cardiomyopathy treatment market is segmented on the basis of drug, indication, distribution channel and end-users. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

  • On the basis of product type, the transthyretin amyloid cardiomyopathy treatment market is segmented into inostersen, nonsteroidal anti-inflammatory drugs (NSAID), partisiran, tafamidis and others.
  • On the basis of Indication, the transthyretin amyloid cardiomyopathy treatment market is segmented into wild type ATTR amyloidosis and hereditary ATTR amyloidosis.
  • On the basis of distribution channel, the transthyretin amyloid cardiomyopathy treatment market is segmented into hospital pharmacy, retail pharmacy and online pharmacy.
  • On the basis of end-users, the transthyretin amyloid cardiomyopathy treatment market is segmented into hospitals, homecare, specialty clinics and others.

Transthyretin Amyloid Cardiomyopathy Treatment Market Country Level Analysis

The transthyretin amyloid cardiomyopathy treatment market is analyzed and market size information is provided by country, drug, indication, distribution channel and end-users as referenced above.

The countries covered in the global transthyretin amyloid cardiomyopathy treatment market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).

North America dominates the transthyretin amyloid cardiomyopathy treatment market due to the increase in the number of diagnosis procedures and presence of leading manufacturers within the region. Asia-Pacific is expected to witness high growth during the forecast period of 2022 to 2029 because of the expansion of the pharmaceutical industry in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

The transthyretin amyloid cardiomyopathy treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Competitive Landscape and Transthyretin Amyloid Cardiomyopathy Treatment Market Share Analysis

The transthyretin amyloid cardiomyopathy treatment market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related transthyretin amyloid cardiomyopathy treatment market.

Some of the major players operating in the transthyretin amyloid cardiomyopathy treatment market are Merck & Co., Inc., Pfizer Inc., AstraZeneca, Prothena Corporation plc., Ionis Pharmaceuticals, BELLUS Health Inc., Alnylam Pharmaceuticals, Inc.., Prothena, GlaxoSmithKline plc., Eidos Therapeutics, and SOM BIOTECH, among others.


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Free Sample Report

CHOOSE LICENCE TYPE

  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials